KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Asset Writedowns and Impairment: 2010-2019

  • Emergent BioSolutions' Asset Writedowns and Impairment was N/A to $12.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $14.1 million, marking a year-over-year change of. This contributed to the annual value of $27.2 million for FY2024, which is 91.13% down from last year.
  • As of Q4 2019, Emergent BioSolutions' Asset Writedowns and Impairment stood at $12.0 million, which was up 5,140.17% from $229,000 recorded in Q2 2018.
  • Emergent BioSolutions' 5-year Asset Writedowns and Impairment high stood at $12.0 million for Q4 2019, and its period low was $34,000 during Q1 2018.
  • For the 2-year period, Emergent BioSolutions' Asset Writedowns and Impairment averaged around $4.1 million, with its median value being $229,000 (2018).
  • Data for Emergent BioSolutions' Asset Writedowns and Impairment shows a maximum YoY crashed of 73.19% (in 2016) over the last 5 years.
  • Over the past 4 years, Emergent BioSolutions' Asset Writedowns and Impairment (Quarterly) stood at $9.8 million in 2015, then tumbled by 73.19% to $1.9 million in 2016, then reached $229,000 in 2018, then reached $12.0 million in 2019.
  • Its last three reported values are $12.0 million in Q4 2019, $229,000 for Q2 2018, and $34,000 during Q1 2018.